NCT02628574View on ClinicalTrials.gov

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab

PHASE1CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

July 14, 2020

Study Completion Date

July 14, 2020

Conditions
Solid Tumors
Interventions
DRUG

TRX518 monotherapy

comparison of different (ascending) doses of TRX518 monotherapy

DRUG

TRX518 with gemcitabine

comparison of different (ascending) doses of TRX518 in combination with gemcitabine

DRUG

TRX518 with pembrolizumab

comparison of different (ascending) doses of TRX518 in combination with pembrolizumab

DRUG

TRX518 with nivolumab

comparison of different (ascending) doses of TRX518 in combination with nivolumab

Trial Locations (6)

15232

University of Pittsburgh Medical Center, Pittsburgh

37205

Tennessee Oncology, Nashville

44106

University Hospitals, Cleveland

44195

Cleveland Clinic, Cleveland

60637

University of Chicago, Chicago

87131

University of New Mexico Comprehensive Cancer Center, Albuquerque

Sponsors
All Listed Sponsors
lead

Leap Therapeutics, Inc.

INDUSTRY